Company description

ACAD is a biopharmaceutical company that specializes in developing small molecule drugs for central nervous system disorders. Founded in 1993, ACAD has become a leader in the industry, known for its commitment to improving the lives of patients with neurological and psychiatric disorders. The company's focus is on discovering and developing innovative treatments for diseases such as schizophrenia, Alzheimer's disease, and Parkinson's disease, specifically targeting the underlying causes of these conditions. ACAD's flagship drug, Nuplazid, received FDA approval in 2016 as the first and only treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company has also developed a diverse pipeline of potential new therapies, utilizing its proprietary chemistry technology to design and synthesize novel compounds. With a dedicated team of experienced scientists and clinicians, ACAD is dedicated to making a positive impact in the lives of patients and their families. The company's stock, traded under the ticker ACAD, continues to perform strongly as ACAD expands its global presence and strengthens its position in the CNS market. Overall, ACAD is a company driven by innovation and a strong commitment to improving the well-being of individuals living with neurological and psychiatric disorders.